Optiscan Initiates FDA Feedback for Oral Cancer 510(k) Submission

Optiscan requests meeting with the US Food and Drug Administration (FDA) to discuss a 510(k) submission to enable the legal sale in the United States of the Optiscan system in oral cancer screening and /or surgery.

See Full Announcement